Press Releases

Tubulis Publishes Deep-dive into Proprietary P5-Conjugation Technology in European Journal of Organic Chemistry

Our peer-reviewed publication on novel linker molecules for our proprietary P5-conjugation platform to develop ADCs with higher stability is now available openly at the European Journal of Organic Chemistry.

The publication gives further insights in how we leverage linker molecules that carry two phosphonamidate electrophiles to develop protein-protein constructs and homogenous ADCs. By using a third chemoselective modification we were also able to attach a fluorophore to the ADC, enabling the direct visualization of cellular ADC uptake.

The full publication can be found here.

Contacts

For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682
Email: tubulis@trophic.eu

Share Article

More Press Releases

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024